KROS
Keros Therapeutics Inc
NASDAQ: KROS · HEALTHCARE · BIOTECHNOLOGY
$11.12
+0.18% today
Updated 2026-04-30
Market cap
$228.75M
P/E ratio
5.03
P/S ratio
0.94x
EPS (TTM)
$2.30
Dividend yield
—
52W range
$10 – $23
Volume
0.4M
Keros Therapeutics Inc (KROS) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $7.04M | $-16.00M | $-36.89M | $-62.15M | $-70.06M | $-124.51M | $-160.87M | $107.50M |
| Capital expenditures | $217000.00 | $270999.00 | $294000.00 | $1.02M | $1.24M | $2.46M | $1.93M | $1.55M |
| Depreciation | — | — | — | — | — | — | — | — |
| Stock-based comp | $81000.00 | $59000.00 | $4.10M | $11.72M | $18.68M | $28.76M | $34.87M | $28.70M |
| Free cash flow | $6.83M | $-16.27M | $-37.19M | $-63.17M | $-71.30M | $-126.97M | $-162.80M | $105.95M |
| Investing cash flow | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | $258.86M | $-34.62M | $49.01M | — | — | — |